KR20220116154A - 항-cd19 항체 및 감마 델타 t-세포를 포함하는 항-종양 병용 요법 - Google Patents

항-cd19 항체 및 감마 델타 t-세포를 포함하는 항-종양 병용 요법 Download PDF

Info

Publication number
KR20220116154A
KR20220116154A KR1020227018073A KR20227018073A KR20220116154A KR 20220116154 A KR20220116154 A KR 20220116154A KR 1020227018073 A KR1020227018073 A KR 1020227018073A KR 20227018073 A KR20227018073 A KR 20227018073A KR 20220116154 A KR20220116154 A KR 20220116154A
Authority
KR
South Korea
Prior art keywords
cells
antibody
antibody fragment
ser
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227018073A
Other languages
English (en)
Korean (ko)
Inventor
얀 엔델
라이너 복스하머
도미니크 프레처
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20220116154A publication Critical patent/KR20220116154A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227018073A 2019-10-31 2020-10-30 항-cd19 항체 및 감마 델타 t-세포를 포함하는 항-종양 병용 요법 Pending KR20220116154A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206479 2019-10-31
EP19206479.8 2019-10-31
PCT/EP2020/080494 WO2021084063A1 (en) 2019-10-31 2020-10-30 Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells

Publications (1)

Publication Number Publication Date
KR20220116154A true KR20220116154A (ko) 2022-08-22

Family

ID=68424789

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018073A Pending KR20220116154A (ko) 2019-10-31 2020-10-30 항-cd19 항체 및 감마 델타 t-세포를 포함하는 항-종양 병용 요법

Country Status (23)

Country Link
US (1) US20210130461A1 (enExample)
EP (2) EP4706673A3 (enExample)
JP (2) JP7688025B2 (enExample)
KR (1) KR20220116154A (enExample)
CN (1) CN115151565A (enExample)
AU (1) AU2020372646A1 (enExample)
DK (1) DK4051710T3 (enExample)
ES (1) ES3062643T3 (enExample)
FI (1) FI4051710T3 (enExample)
HR (1) HRP20251630T1 (enExample)
IL (1) IL292213A (enExample)
LT (1) LT4051710T (enExample)
MA (1) MA69251B1 (enExample)
MD (1) MD4051710T2 (enExample)
MX (1) MX2022005033A (enExample)
PH (1) PH12022551009A1 (enExample)
PL (1) PL4051710T3 (enExample)
PT (1) PT4051710T (enExample)
RS (1) RS67602B1 (enExample)
SI (1) SI4051710T1 (enExample)
SM (1) SMT202600082T1 (enExample)
TW (2) TWI922280B (enExample)
WO (1) WO2021084063A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024058534A1 (ko) 2022-09-15 2024-03-21 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2710123B1 (en) 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
EP3157553A4 (en) * 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
JP6916741B2 (ja) * 2015-05-26 2021-08-11 モルフォシス・アーゲー 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． ＴＣＲγδ＋Ｔ細胞の生産方法
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
CN118421557A (zh) 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) * 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
EP3532091A2 (en) * 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024058534A1 (ko) 2022-09-15 2024-03-21 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Also Published As

Publication number Publication date
MA69251B1 (fr) 2025-12-31
TW202547555A (zh) 2025-12-16
WO2021084063A1 (en) 2021-05-06
DK4051710T3 (da) 2025-12-15
AU2020372646A1 (en) 2022-05-12
PH12022551009A1 (en) 2023-03-20
SI4051710T1 (sl) 2026-01-30
ES3062643T3 (en) 2026-04-13
TWI883067B (zh) 2025-05-11
IL292213A (en) 2022-06-01
JP7688025B2 (ja) 2025-06-03
EP4706673A3 (en) 2026-05-20
EP4051710B1 (en) 2025-11-26
LT4051710T (lt) 2026-03-10
CA3158984A1 (en) 2021-05-06
TWI922280B (zh) 2026-04-11
US20210130461A1 (en) 2021-05-06
MX2022005033A (es) 2022-09-09
RS67602B1 (sr) 2026-01-30
SMT202600082T1 (it) 2026-03-09
JP2022554324A (ja) 2022-12-28
CN115151565A (zh) 2022-10-04
PL4051710T3 (pl) 2026-04-20
JP2025134705A (ja) 2025-09-17
HRP20251630T1 (hr) 2026-02-13
TW202131949A (zh) 2021-09-01
PT4051710T (pt) 2026-02-09
EP4051710A1 (en) 2022-09-07
EP4706673A2 (en) 2026-03-11
MD4051710T2 (ro) 2026-04-30
FI4051710T3 (fi) 2026-01-12

Similar Documents

Publication Publication Date Title
TWI902626B (zh) 嵌合抗原及t細胞受體以及使用方法
TWI883067B (zh) 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
US20240209061A1 (en) Fusion proteins and uses thereof
JP2022503685A (ja) 抗ｃｄ１９抗体及びナチュラルキラー細胞を含む、腫瘍を治療する薬学的組み合わせ
CN114601931A (zh) 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
EP4543468A2 (en) Dosing regimens for cd19-directed cancer immunotherapy
CA3158984C (en) Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
EA050676B1 (ru) Противоопухолевая комбинированная терапия, включающая антитело к cd19 и гамма-дельта т-клетки
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
AU2020209425B2 (en) Antibody
KR20250060146A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
HK40128442A (en) Chimeric antigen and t cell receptors and methods of use
HK40126667A (en) Chimeric antigen and t cell receptors and methods of use
HK40061606B (en) Chimeric antigen receptors and car-t cells and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D13 Search requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D13-SRH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902